Sign inJoin waitlistJoin the waitlist

Maryam Fouladi

Named Co-Executive Director of Pediatric Neuro-Oncology Program · Nationwide Children's Hospital

Credentials: · · · ·

History

Pediatric Neuro-Oncology Program · Nationwide Children's Hospital
Present
Nationwide Children's Hospital
Present
Nationwide Children's Hospital
Present

Research

Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma
Cancer Cell · 2012 · 1,470 citations
Intertumoral Heterogeneity within Medulloblastoma Subgroups
Cancer Cell · 2017 · 970 citations
Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma
Systematic review or meta-analysis · Cancer Cell · 2017 · 918 citations

Amar Gajjar
63 papers
Roger Packer
39 papers
LK
Larry Kun
38 papers
Ian Pollack
34 papers
Stewart Goldman
32 papers
Sarah Leary
30 papers
CF
Christine Fuller
26 papers
MD
Mariko Dewire-Schottmiller
26 papers
Thomas Merchant
23 papers
JF
Jason Fangusaro
22 papers
LH
Lindsey Hoffman
21 papers
James Leach
20 papers

Grants

Phase II, Multi-Arm, Molecularly-Guided Umbrella Trial for Children and Young Adults with High-Grade Glioma
Food and Drug Administration · R01
Contact PI · $3.2M · Research Inst Nationwide Children's Hosp
2025–2029
IND:138100. A Phase I and Surgical Cohort Study of PTC596 in Newly Diagnosed Children with DIPG and High-Grade Gliomas
Food and Drug Administration · R01
Contact PI · $750K · Research Inst Nationwide Children's Hosp
2019–2024
Pediatric Brain Tumor Consortium A Multi-Institutional Consortium Devoted to Novel Phase I and II Clinical Evaluations of Experimental Treatment Approaches for Pediatric CNS Tumors
National Cancer Institute · UM1
PI · $5.6M · St. Jude Children's Research Hospital
1999–2019
Lapatinib in Childhood CNS Malignancies
National Cancer Institute · R21
Contact PI · $585.5K · St. Jude Children's Research Hospital
2005–2008

Clinical trials

Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma
Principal investigator · Not yet recruiting · Phase 3
Nationwide Children's Hospital
2026–2038
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
Principal investigator · Recruiting · Early phase 1
Nationwide Children's Hospital
2025–2035
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Principal investigator · Recruiting · Phase 2
Nationwide Children's Hospital
2024–2034
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
Principal investigator · Recruiting · Phase 2
Nationwide Children's Hospital
2024–2030